Press Releases

– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Apr. 1, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 27, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023 , on Monday, April 1, 2024 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--Feb. 20, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – SEATTLE --(BUSINESS WIRE)--Feb. 1, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI

– Conference Call Today at 1:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023 , on Thursday, November 9, 2023 , after the market closes. Omeros management will host a conference call and

-- Poster Presentation Slated for Upcoming Annual Meeting of the American Society of Hematology -- SEATTLE --(BUSINESS WIRE)--Nov. 3, 2023-- Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with

-- New and Updated Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE --(BUSINESS WIRE)--Nov. 2, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational

SEATTLE --(BUSINESS WIRE)--Oct. 19, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer , M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical

The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials Webcast conference call

– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023 , on Wednesday, August 9, 2023 , before the market opens. Omeros management will host a conference call and webcast that

SEATTLE --(BUSINESS WIRE)--Jun. 21, 2023-- Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023 , starting at 10:00 a.m. Pacific Time .

SEATTLE --(BUSINESS WIRE)--Jun. 12, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .

– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation – SEATTLE --(BUSINESS WIRE)--Jun. 1, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--May 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023 , on Tuesday, May 9, 2023 , after the market closes. Omeros management will host a conference call and

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an increase in

–   Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder – SEATTLE --(BUSINESS WIRE)--Apr. 10, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 10, 2023-- Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank . Omeros previously maintained a line of credit with Silicon Valley Bank , which the company

SEATTLE --(BUSINESS WIRE)--Mar. 7, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022 , on Monday, March 13, 2023 , after the market closes.

– OMIDRIA ® -Related Payment Expected to Provide Operating Capital into at Least 2025 – SEATTLE --(BUSINESS WIRE)--Feb. 6, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 9, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

-- Decision Denies Omeros’ Appeal Requesting Immediate Labeling Discussions -- -- Decision Proposes a Path Forward Based on Historical Survival Data -- SEATTLE --(BUSINESS WIRE)--Nov. 8, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S.

SEATTLE --(BUSINESS WIRE)--Nov. 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022 , on Wednesday, November 9, 2022 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Nov. 3, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December

-- Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA – SEATTLE --(BUSINESS WIRE)--Oct. 3, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly

-- Reduction in Mortality Risk with Narsoplimab -- SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC).

SAN FRANCISCO & SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed

SEATTLE --(BUSINESS WIRE)--Aug. 17, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022 , on Tuesday, August 9, 2022 , after the market closes. Omeros management will host a conference call and

- - Enrollment of PNH Patients Expected to Begin this Summer -- SEATTLE --(BUSINESS WIRE)--Jul. 29, 2022-- Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria

SEATTLE --(BUSINESS WIRE)--Jun. 15, 2022-- Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022 , starting at 10:00 a.m. Pacific Time .

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022 , on Tuesday, May 10, 2022 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--Apr. 20, 2022-- Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 24, 2022-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021 , on Tuesday, March 1, 2022 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Jan. 19, 2022-- Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic

SEATTLE --(BUSINESS WIRE)--Dec. 23, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc . , an affiliate of Rayner Surgical Group Limited .

-- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 Inhibitors – -- Conference call today at 8:30 a.m. ET , 5:30 a.m. PT --   $125 million upfront payment and $200 million on achievement of commercial milestone Royalties

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

-- Data Show Improvement and Stabilization in Renal Function -- Unprecedented median proteinuria reduction of 64.4 percent seen in the narsoplimab Phase 2 clinical trial predicts a 41.6-year delay in need for dialysis compared to standard of care Narsoplimab is the first candidate targeting IgA

-- First Report of Narsoplimab’s Effects on Complement Activation Markers in Renal Disease Presented at the Annual Meeting of the American Society of Nephrology -- SEATTLE --(BUSINESS WIRE)--Nov. 5, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the

SEATTLE --(BUSINESS WIRE)--Nov. 4, 2021-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021 , on Tuesday, November 9, 2021 , after the market closes.

-- Conference call today at 8:30 a.m. ET , 5:30 a.m. PT -- SEATTLE --(BUSINESS WIRE)--Oct. 18, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License

SEATTLE --(BUSINESS WIRE)--Oct. 1, 2021-- Omeros Corporation  (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 3, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021 , on Monday, August 9, 2021 , after the market closes. Omeros management will host a conference call and

-- Data on Organ Function Improvement Presented by Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering -- SEATTLE --(BUSINESS WIRE)--Jun. 14, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab

-- Inhibitors of PDE7 Enzymes Could Treat Nicotine Abuse -- SEATTLE --(BUSINESS WIRE)--Jun. 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as

SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff

-- Results show good safety and PK/PD profile consistent with low-dose, once-monthly subcutaneous dosing -- SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing

-- Study Patients Comprise Second Cohort from Bergamo, Italy -- SEATTLE --(BUSINESS WIRE)--May 28, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market

-- PDUFA Date is October 17, 2021 -- SEATTLE --(BUSINESS WIRE)--May 20, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 5, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021 , on Monday, May 10, 2021 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--May 4, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention ( CDC ) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated

-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients -- SEATTLE & SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2021-- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 25, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020 , on Monday, March 1, 2021 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Jan. 26, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial

-- FDA sets PDUFA date of July 17, 2021 -- SEATTLE --(BUSINESS WIRE)--Jan. 19, 2021-- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy

SEATTLE --(BUSINESS WIRE)--Jan. 11, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference

— Separate payment for OMIDRIA retroactively effective as of October 1, 2020 — SEATTLE --(BUSINESS WIRE)--Dec. 3, 2020-- Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for

-- Priority Review Requested -- SEATTLE --(BUSINESS WIRE)--Nov. 18, 2020-- Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of

SEATTLE --(BUSINESS WIRE)--Nov. 9, 2020-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

SEATTLE --(BUSINESS WIRE)--Nov. 5, 2020-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020 , on Monday, November 9, 2020 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Oct. 28, 2020-- Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital

-- Webcast Scheduled for Today at 8:30am ET -- SEATTLE --(BUSINESS WIRE)--Oct. 22, 2020-- Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal

  SEATTLE --(BUSINESS WIRE)--Oct. 16, 2020-- Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3

-- Efficacy Results Surpass Those from Preliminary Analysis Previously Reported -- SEATTLE --(BUSINESS WIRE)--Oct. 15, 2020-- Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell

—OMIDRIA meets all objective criteria established by CMS— SEATTLE --(BUSINESS WIRE)--Oct. 1, 2020-- Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.3% .

SEATTLE --(BUSINESS WIRE)--Sep. 11, 2020-- Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The presentation is scheduled for Tuesday, September 15,

- Omeros’ investigational agent narsoplimab discussed as a potentially highly effective therapy - SEATTLE --(BUSINESS WIRE)--Sep. 3, 2020-- Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of

-- Paroxysmal Nocturnal Hemoglobinuria Slated as Initial Indication -- SEATTLE --(BUSINESS WIRE)--Aug. 31, 2020-- Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S.

--6,900,000 Shares of Common Stock-- -- $210,000,000 of 5.25% Convertible Senior Notes due 2026-- SEATTLE --(BUSINESS WIRE)--Aug. 12, 2020-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common

SEATTLE --(BUSINESS WIRE)--Aug. 10, 2020-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the “Shares”) and $200,000,000 aggregate principal amount of convertible senior notes

SEATTLE --(BUSINESS WIRE)--Aug. 10, 2020-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

-- All six patients, requiring mechanical ventilation prior to treatment, recovered, survived and were discharged from the hospital -- Narsoplimab treatment was associated with rapid and sustained improvement across all assessed markers of endothelial/cellular damage and/or inflammation -- Omeros

SEATTLE --(BUSINESS WIRE)--Jun. 12, 2020-- Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the

SEATTLE --(BUSINESS WIRE)--Jun. 11, 2020-- Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of

SEATTLE --(BUSINESS WIRE)--May 14, 2020-- Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25 th Annual Congress of the

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 11, 2020-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 5, 2020-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020 , on Monday, May 11, 2020 , after the market closes. Omeros management will host a conference call and

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications

– Results Surpass FDA-Agreed Efficacy Threshold – SEATTLE --(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA),

SEATTLE --(BUSINESS WIRE)--Feb. 24, 2020-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019 , on Monday, March 2, 2020 , after the market closes.

-- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- SEATTLE --(BUSINESS WIRE)--Feb. 11, 2020-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt , former global treasurer of Amazon.com, Inc.

AMSTERDAM & SEATTLE --(BUSINESS WIRE)--Dec. 18, 2019-- myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a

SEATTLE --(BUSINESS WIRE)--Dec. 16, 2019-- Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology ( ESMO ) 2019 Immuno-Oncology Congress in Geneva, Switzerland .

SEATTLE --(BUSINESS WIRE)--Dec. 13, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

SEATTLE --(BUSINESS WIRE)--Dec. 10, 2019-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress , which is being held December 11-14, 2019 in

SEATTLE --(BUSINESS WIRE)--Dec. 5, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

SEATTLE --(BUSINESS WIRE)--Dec. 4, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA ; 68 Percent Primary-Endpoint Complete Response Rate for Those Who Received Protocol-Specified Treatment of At Least 4 Weeks of Dosing – – 100-Day

SEATTLE --(BUSINESS WIRE)--Nov. 20, 2019-- Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts .

-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- SEATTLE --(BUSINESS WIRE)--Nov. 19, 2019-- Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in

Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Nov. 8, 2019-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American

--Prestigious Prize Conferred for GPCR Program Discoveries-- SEATTLE --(BUSINESS WIRE)--Nov. 7, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A.

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019 , on Tuesday, November 12, 2019 , after the market closes.

-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- SEATTLE --(BUSINESS WIRE)--Nov. 4, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA -approved ophthalmic drug OMIDRIA ®

– Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application – SEATTLE --(BUSINESS WIRE)--Oct. 29, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion

– Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – SEATTLE --(BUSINESS WIRE)--Oct. 28, 2019-- Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S.

  SEATTLE --(BUSINESS WIRE)--Oct. 1, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to

  SEATTLE --(BUSINESS WIRE)--Sep. 25, 2019-- Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria ( i.e.

-- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- SEATTLE --(BUSINESS WIRE)--Sep. 16, 2019-- Omeros Corporation (Nasdaq: OMER) today announced positive results from its Phase 1 study with the lead compound in its OMS527 program.

– Omeros Remains On Track to Initiate the Submission Next Quarter – SEATTLE --(BUSINESS WIRE)--Sep. 11, 2019-- Omeros Corporation (Nasdaq: OMER) announced that the United States Food and Drug Administration ( FDA ) agreed with the company’s proposed schedule for the rolling review of the Biologics

-- The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- SEATTLE --(BUSINESS WIRE)--Sep. 10, 2019-- Omeros Corporation (Nasdaq: OMER) today announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the

SEATTLE --(BUSINESS WIRE)--Sep. 6, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21 st Annual Global Investment Conference in New York next week.

SEATTLE --(BUSINESS WIRE)--Aug. 9, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday,

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 8, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 5, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019 , on Thursday, August 8, 2019 , after the market closes.

SEATTLE & BASEL, Switzerland --(BUSINESS WIRE)--Jul. 31, 2019-- Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated

-- Effective October 1, 2019 , New Code Expected to Expand Reimbursement -- SEATTLE --(BUSINESS WIRE)--Jul. 24, 2019-- Omeros Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare

-- All Criteria for the Response-Based Endpoint Now Finalized -- SEATTLE --(BUSINESS WIRE)--Jul. 11, 2019-- Omeros Corporation today announced agreement with the U.S. Food and Drug Administration ( FDA ) on the response-based primary endpoint for its pivotal trial to support the biologics license

– Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA)

SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- SEATTLE --(BUSINESS WIRE)--May 7, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA -approved ophthalmic drug

SEATTLE --(BUSINESS WIRE)--May 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after the market closes. Omeros management will host a conference call

SEATTLE --(BUSINESS WIRE)--May 1, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA -approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American

-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of

--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and

– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens.

SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary

Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has

-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.

--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent

– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .

-- Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research -- SEATTLE --(BUSINESS WIRE)--Dec. 20, 2018-- Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for

Newly Established Center Will Focus on Complement and Inflammation SEATTLE --(BUSINESS WIRE)--Dec. 11, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge , establishing the Omeros Center at Cambridge for

– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review – SEATTLE --(BUSINESS WIRE)--Dec. 6, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment

-- Hires Commercial and CMC Heads from Celgene -- SEATTLE --(BUSINESS WIRE)--Dec. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue , Ph.D.

-- Initial Purchasers Have Option to Purchase $40 Million of Additional Notes -- SEATTLE --(BUSINESS WIRE)--Nov. 9, 2018-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due

SEATTLE , Nov. 8, 2018 /PRNewswire/ --  Omeros Corporation (Nasdaq: OMER) (" Omeros ") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the

– Conference Call Friday, November 9th at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Nov. 8, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018 , which include: 3Q 2018 total and

SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018 , on Friday, November 9, 2018 , before the market opens.

-- OMS721 now with orphan designation covering both prevention and treatment of HSCT-TMA in U.S. and in Europe -- SEATTLE --(BUSINESS WIRE)--Oct. 23, 2018-- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S.

-- Magnitude of Proteinuria Reduction Consistent With Previous Cohort -- SEATTLE --(BUSINESS WIRE)--Oct. 1, 2018-- Omeros Corporation  (NASDAQ: OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases.

-- CMS’ Separate Payment for Cataract Surgery Drug Resumes Today -- SEATTLE --(BUSINESS WIRE)--Oct. 1, 2018-- Omeros Corporation  (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company’s

SEATTLE --(BUSINESS WIRE)--Sep. 27, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, October

SEATTLE --(BUSINESS WIRE)--Sep. 7, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16 th Annual Morgan Stanley Global Healthcare Conference in New York next week.

SEATTLE --(BUSINESS WIRE)--Aug. 28, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).

SEATTLE --(BUSINESS WIRE)--Aug. 10, 2018-- Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday,

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018 , which include: 2Q 2018 total and OMIDRIA ® revenues were

SEATTLE --(BUSINESS WIRE)--Aug. 3, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018 , on Thursday, August 9, 2018 , after the market closes.

– Company Expands Leadership to Keep Pace with Advancing Pivotal Clinical Programs – SEATTLE --(BUSINESS WIRE)--Aug. 2, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that Eckhard Leifke, M.D. has been named Omeros’ Chief Medical Officer and Vice President of Clinical Development.

-- With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation -- SEATTLE --(BUSINESS WIRE)--Jul. 26, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc.

-- Discussions Ongoing with European Regulators for Pathway to Expedited Approval -- SEATTLE --(BUSINESS WIRE)--Jul. 25, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion

-- Sales maintain the drug’s European marketing authorization -- SEATTLE --(BUSINESS WIRE)--Jul. 23, 2018-- Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe .

-- Nicotine Addiction Planned as First Indication -- SEATTLE --(BUSINESS WIRE)--Jul. 17, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in

– First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction – SEATTLE --(BUSINESS WIRE)--Jun. 27, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead

--Lupin Confirms Validity of OMIDRIA Patents-- SEATTLE --(BUSINESS WIRE)--May 24, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018 , which include: 1Q 2018 total and OMIDRIA ® revenues were

SEATTLE --(BUSINESS WIRE)--May 7, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018 , on Thursday, May 10, 2018 , after the market closes. Omeros management will host a conference call

– Discussions Ongoing with FDA and European Regulators for Expedited Approval – SEATTLE --(BUSINESS WIRE)--Apr. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) has granted breakthrough therapy designation to OMS721 for the treatment of

-- OMIDRIA demonstrates clear benefits across traditional and femtosecond laser-assisted cataract surgery and in IFIS cases-- SEATTLE --(BUSINESS WIRE)--Apr. 19, 2018-- Omeros Corporation  (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of

SEATTLE --(BUSINESS WIRE)--Apr. 13, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive

-- OMIDRIA now available across the VA system to benefit U.S. veterans -- SEATTLE --(BUSINESS WIRE)--Apr. 12, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA ® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA

SEATTLE --(BUSINESS WIRE)--Apr. 11, 2018-- Omeros Corporation  (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP , a healthcare-focused investment firm. With respect to the twelve-month period beginning on January

Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Mar. 1, 2018-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017 , on Thursday, March 1, 2018 , after the market closes.

-- Greater than 16-Fold Improvement in Survival Compared to Historical Control -- SEATTLE --(BUSINESS WIRE)--Feb. 15, 2018-- Omeros Corporation (NASDAQ: OMER) today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell

-- EMA also reviewing Priority Medicines application for the drug in IgAN -- SEATTLE --(BUSINESS WIRE)--Jan. 22, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Omeros’

-- Also Initiates OMS721 Phase 3 Program in HCT-TMA -- SEATTLE --(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration ( FDA ) on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in

-- FDA Also Grants Additional Market Exclusivity -- SEATTLE --(BUSINESS WIRE)--Dec. 12, 2017-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 9, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans .

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2017 financial results for the period ended September 30, 2017 , on Thursday, November 9, 2017 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Nov. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that a subset of data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for

-- Preparing to Initiate Phase 3 Clinical Program -- SEATTLE , Oct. 26, 2017 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced further positive data from the company's ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic

-- Results May Expand Target for Omeros’ Planned Phase 3 Program in HCT-TMA -- SEATTLE --(BUSINESS WIRE)--Oct. 20, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic

SEATTLE --(BUSINESS WIRE)--Oct. 16, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for the

--Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032-- SEATTLE --(BUSINESS WIRE)--Oct. 5, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc.

SEATTLE --(BUSINESS WIRE)--Aug. 23, 2017-- Omeros Corporation (NASDAQ:OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies

SEATTLE --(BUSINESS WIRE)--Aug. 21, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that on August 18, 2017 , as scheduled, it closed the underwritten public offering that was priced on August 14, 2017 , relating to the sale of 3,000,000 shares of its common stock at a price to the public

SEATTLE --(BUSINESS WIRE)--Aug. 15, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

SEATTLE --(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

– Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data – SEATTLE --(BUSINESS WIRE)--Aug. 14, 2017-- Omeros Corporation  (NASDAQ: OMER) today announced additional follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 in the Phase 2

SEATTLE --(BUSINESS WIRE)--Aug. 10, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 8, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

- Initiating Phase 3 Program for OMS721 in IgA Nephropathy with Both Breakthrough and Orphan Designations - SEATTLE --(BUSINESS WIRE)--Aug. 4, 2017-- Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S.

SEATTLE --(BUSINESS WIRE)--Aug. 2, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter 2017 financial results for the period ended June 30, 2017 , on Tuesday, August 8, 2017 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Jun. 29, 2017-- Omeros Corporation (NASDAQ: OMER) stated today that it is aware of a report posted on-line by “Art Doyle,” an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one or more employers.

- Omeros’ Second Phase 3 Clinical Program for OMS721 Slated to Begin this Year - SEATTLE --(BUSINESS WIRE)--Jun. 13, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration ( FDA ) has granted breakthrough therapy designation to OMS721 for the treatment of

SEATTLE --(BUSINESS WIRE)--Jun. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the company’s Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th European Renal

-- Additional Positive Results Support Rapid Advancement to Phase 3 Trial -- SEATTLE --(BUSINESS WIRE)--May 17, 2017-- Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--May 10, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE --(BUSINESS WIRE)--May 3, 2017-- Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its first quarter 2017 financial results for the period ended March 31, 2017 , on Wednesday, May 10, 2017 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Apr. 3, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16 th Annual Needham Healthcare Conference in New York City this week.

-- Phase 3 Program Slated for This Year -- SEATTLE --(BUSINESS WIRE)--Mar. 30, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage

-- Additional Positive “Challenge-Rechallenge” Data Reported in Patient with Stem Cell Transplant-Associated TMA -- SEATTLE --(BUSINESS WIRE)--Mar. 28, 2017-- Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell

SEATTLE, Wash. --(BUSINESS WIRE)--Mar. 27, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next month at the International

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Mar. 16, 2017-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 10, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016 , on Thursday, March 16, 2017 , after the market closes.

SEATTLE --(BUSINESS WIRE)--Mar. 2, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cowen and Company 37 th Annual Health Care Conference in Boston, MA next week.

--Data Presented at the Recent Combined International and American Blood & Marrow Transplantation Meetings-- SEATTLE --(BUSINESS WIRE)--Mar. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the

-- Presentation Will Highlight Efficacy and Safety Results -- SEATTLE --(BUSINESS WIRE)--Dec. 7, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem cell

-- 15 Year-Old with Stem Cell Transplant-Associated TMA Had Previously Developed Additional Life-Threatening Condition while on Soliris ® -- SEATTLE --(BUSINESS WIRE)--Dec. 6, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced that, following physician request, it will provide continued

-- Small-Molecule Inhibitors Enhance Immune System and May Offer Advantages over Existing Cancer Therapies -- SEATTLE --(BUSINESS WIRE)--Dec. 5, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR)

-- NEURON-Funded Program Will Evaluate Benefits of Omeros’ MASP-2 Antibody -- SEATTLE --(BUSINESS WIRE)--Nov. 30, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy , United Kingdom , Germany , Spain and Poland was awarded €1.3

-- Six-Month Extension of Patent Exclusivity and Label Expansion Expected -- SEATTLE --(BUSINESS WIRE)--Nov. 21, 2016-- Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA ® (phenylephrine and

-- Non-Human Primate Data Support Advancing to Clinic -- SEATTLE --(BUSINESS WIRE)--Nov. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates. OMS906 inhibits mannan-binding lectin-associated serine

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Nov. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE --(BUSINESS WIRE)--Nov. 7, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

SEATTLE --(BUSINESS WIRE)--Nov. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has completed the initial funding under its senior secured credit facility with affiliates of CRG LP , a healthcare-focused investment firm, consisting of an $80 million term loan.

-- Omeros Continues to Expand Orphan Indications for OMS721 -- SEATTLE --(BUSINESS WIRE)--Nov. 3, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an application for orphan drug designation with the U.S. Food and Drug Administration ( FDA ) for OMS721 in the treatment of

– Decreases Craving and Anxiety in Heroin-Dependent Patients – SEATTLE --(BUSINESS WIRE)--Nov. 2, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in

-- Phase 3 Clinical Program Planned for 2017 -- SEATTLE --(BUSINESS WIRE)--Oct. 31, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has requested fast track designation from the U.S. Food and Drug Administration ( FDA ) for the development of OMS721 for the treatment of patients

SEATTLE --(BUSINESS WIRE)--Oct. 27, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has entered into a senior credit facility with CRG LP , a healthcare-focused investment firm, to retire the company’s existing credit facility, minimizing restricted cash requirements and providing

-- Targeted Indications for the Company’s MASP-2 Inhibitor Continue to Expand -- SEATTLE --(BUSINESS WIRE)--Oct. 20, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from

-- Decreases Craving and Protects Brain White Matter Integrity -- SEATTLE --(BUSINESS WIRE)--Oct. 19, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist

-- Pursuing Breakthrough Therapy Designation in IgA Nephropathy (Berger’s Disease) -- SEATTLE --(BUSINESS WIRE)--Oct. 17, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which

-- Data Published in Journal of Neuroinflammation -- SEATTLE --(BUSINESS WIRE)--Sep. 8, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS721 complement program. OMS721 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).

SEATTLE --(BUSINESS WIRE)--Aug. 12, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

SEATTLE , Aug. 11, 2016 /PRNewswire/ --  Omeros Corporation  (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering

SEATTLE , Aug. 10, 2016 /PRNewswire/ --  Omeros Corporation  (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co. , as the sole underwriter, in a registered underwritten public offering.

-- Shows Substantial Advantage over C5 Inhibitor -- SEATTLE --(BUSINESS WIRE)--Aug. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3).

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE --(BUSINESS WIRE)--Aug. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Shows Marked Efficacy in Model of Arthritis -- SEATTLE --(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the

-- One Single-Arm, Open-Label Phase 3 Pivotal Trial Planned to Support Approval in Both Europe and the U.S. -- SEATTLE , July 28, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with

SEATTLE --(BUSINESS WIRE)--Jul. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Successful Completion Expected to Lead to Additional Market Exclusivity -- SEATTLE --(BUSINESS WIRE)--Jun. 29, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for

SEATTLE --(BUSINESS WIRE)--May 17, 2016-- Omeros Corporation (NASDAQ: OMER) (the “Company”) today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC (“Oxford”) and East West Bank (“East West”) to provide the Company with an additional $20 million

-- Conference Call Today at 9:00 a.m. ET -- SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Initiates International Market Expansion -- SEATTLE --(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--May 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Studies Assessed Key Surgical Outcome Measures Including Complication Rates -- SEATTLE --(BUSINESS WIRE)--Apr. 26, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for

-- Study Provides an Opportunity for Breakthrough Therapy Designation and Subsequent Accelerated Approval -- SEATTLE --(BUSINESS WIRE)--Apr. 20, 2016-- Omeros Corporation  (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal

SEATTLE --(BUSINESS WIRE)--Apr. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Single Pivotal Study Needed for Phase 3 -- SEATTLE --(BUSINESS WIRE)--Mar. 8, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

Conference Call Tomorrow, March 8 , at 9:00 a.m. ET SEATTLE --(BUSINESS WIRE)--Mar. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Mar. 3, 2016--   Omeros Corporation   (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies

SEATTLE --(BUSINESS WIRE)--Mar. 2, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- OMS721 Requested for Finnish Patient Not Adequately Responsive to Soliris ® -- SEATTLE --(BUSINESS WIRE)--Feb. 24, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for

SEATTLE --(BUSINESS WIRE)--Jan. 15, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and

SEATTLE --(BUSINESS WIRE)--Jan. 6, 2016-- Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank . The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability,

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE , Nov. 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE , Nov. 2, 2015 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Ensures Access to Benefits of Omidria for Cataract Patients, Surgeons and Facilities -- SEATTLE , Oct. 15, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has launched OMIDRIAssure ™ , a comprehensive reimbursement services program to provide expanded access to

SEATTLE , Sept. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC , (collectively "Par") in the U.S.

-- Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients -- SEATTLE , Aug. 18, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies

SEATTLE , Aug. 17, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New

-- Conference Call Today at 4:30 p.m. ET -- SEATTLE , Aug. 10, 2015 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications

SEATTLE , Aug. 7, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- Approval by the European Commission Follows Unanimous Recommendation by the EMA -- SEATTLE , Aug. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection)

SEATTLE , July 31, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Phase 2 Trial and Compassionate Use Program Advance -- SEATTLE , July 23, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic

SEATTLE , June 17, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah , M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the company's board of directors. From 2010 to 2015, Dr.

-- U.S. Sales to Begin This Year -- SEATTLE , June 16, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today

- Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile - SEATTLE , May 22, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein

-- Omidria Now Widely Available in the U.S. Following Commercial Launch -- SEATTLE , May 11, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as

SEATTLE , May 5, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment - SEATTLE , April 14, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for

SEATTLE , April 9, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

-- First and Only FDA-Approved Intraocular Product that Prevents Pupil Constriction and Reduces Postoperative Pain -- SEATTLE , April 2, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and

-- 4Q 2014 net loss of $20.7 million, or $0.61 per share -- SEATTLE , March 16, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE , March 9, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and

- The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS - SEATTLE , Feb. 19, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the

SEATTLE , Feb. 3, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share

SEATTLE , Jan. 29, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03 , and pre-funded warrants to purchase up to 749,250 shares of its

SEATTLE , Jan. 28, 2015 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering.

- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE , Nov. 19, 2014 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine

-- Omidria™ U.S. Commercial Launch Planned for Early 2015 -- SEATTLE , Nov. 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

-- Lectin Pathway Identified as Key Contributor to Stroke Sequelae -- SEATTLE , Nov. 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal

SEATTLE , Nov. 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders

-- Unique Billing Code Allows Separate Payment for Omidria -- SEATTLE , Oct. 30, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria ™ (phenylephrine and ketorolac injection) 1%/0.3% from the

-- Enrollment in Huntington's Trial Suspended Pending Further Assessment of Preclinical Data -- SEATTLE , Oct. 21, 2014 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of

-- FDA Approval of Omidria™ Received on May 30, 2014 - SEATTLE , Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE , Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE , June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract

-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE , May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation,

SEATTLE , April 7, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE , April 3, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs)

-- Conference Focuses on New Drug Development and Cutting Edge Research in Schizophrenia -- SEATTLE , April 1, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International

SEATTLE , March 21, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , March 19, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on March 14, 2014 , relating to the sale of 3,500,000 shares of its common

SEATTLE, March 14, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per share for gross proceeds of $35.0 million .

SEATTLE , March 13, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to

-- 4Q 2013 net loss of $1.8 million, or $0.05 per share -- SEATTLE , March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation,

- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE , March 10, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE , March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.

SEATTLE , March 5, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires

-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE , March 4, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration ( FDA ) an investigational new drug

SEATTLE , Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE , Feb. 19, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being

-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses -- SEATTLE , Feb. 11, 2014 /PRNewswire/ -- Omeros Corporation  (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

-- Enrollment in Huntington's Phase 2 Trial Expected Soon -- SEATTLE , Feb. 5, 2014 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation to OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor,

-- Phase 2 Program Expected to Initiate this Quarter -- SEATTLE , Feb. 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding

- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE , Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10)

-- Phase 2 Program Expected to Begin Next Quarter -- SEATTLE , Dec. 18, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the

SEATTLE , Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- European Medicines Agency Review of Proposed Names to be Completed Soon -- SEATTLE , Nov. 20, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that the U.S. Food and Drug Administration ( FDA ) accepted the proposed brand name Omidria™ for OMS302, the Company's proprietary

-- In These Clinical Trials, OMS302 Reduced Incidence of Miosis -- SEATTLE , Nov. 19, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular

-- OMS302 also to be Featured in "Cutting Edge" Symposium -- SEATTLE , Nov. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present data from its Phase 3 clinical program for OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will

-- Phase 2 Program Expected to Begin Enrollment Next Quarter -- SEATTLE , Nov. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive clinical data in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding

-- Obtains Additional $17.4 Million in Cash in 4Q 2013 -- SEATTLE, Wash. , Nov. 7, 2013 /PRNewswire/ -- Received $17.4 million in cash in October 2013 Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash

-- Ongoing Clinical Program for OMS721 Continues to Advance -- SEATTLE , Nov. 5, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in

SEATTLE , Oct. 17, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the " SEC ").

-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses - SEATTLE , Oct. 17, 2013 /PRNewswire/ --   Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

-- Completion of Pediatric Study Can Lead to Additional Marketing Exclusivity - SEATTLE , Oct. 15, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration ( FDA ) confirmed its agreement with the Pediatric Study Plan (PSP) proposed by

SEATTLE , Oct. 8, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company with marketing applications for its lead product OMS302 for use during lens replacement surgery currently under review in both the US and Europe , today announced the appointment of

-- Omeros to Receive $12.5 Million -- SEATTLE , Oct. 3, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced today that it entered into a settlement agreement with its insurer, Carolina Casualty Insurance Company (CCIC), related to CCIC's defense of, and coverage obligations owed to,

-- Brings Omeros' Total to 52 Class A Orphans and Opens Way to New Oral Drugs to Treat Diabetes and Osteoporosis -- SEATTLE , Oct. 3, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of six additional

-- OMS302 Remains on Track for Planned 2014 Commercial Launch -- SEATTLE , Oct. 2, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced today that the New Drug Application (NDA) for its ophthalmology product, OMS302, has been confirmed for filing by the U.S.

-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE , Sept. 30, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S.

SEATTLE , Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- PDE10 Inhibitor Administered to Patients with Schizophrenia -- SEATTLE , Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ:OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.

-- Phase 1 Trial Data Predict Substantially Greater Target Engagement with Better Tolerability Than Seen with Other PDE10 Inhibitors -- SEATTLE , Sept. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the Company's Phase 1 clinical trial evaluating the

- European Market Launch Planned for Second Half of 2014 - SEATTLE , Sept. 10, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market OMS302 for

SEATTLE , Sept. 9, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , Aug. 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, has announced that Michael A.

SEATTLE , Aug. 9, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

SEATTLE , Aug. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the Wedbush

- Submission of European Marketing Authorization Application Planned for this Quarter - SEATTLE , Aug. 1, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) announced that the company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of

-- Submission of Marketing Authorization Application Remains on Track for Mid-Year-- SEATTLE , July 2, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) approved a positive opinion issued by the European Pediatrics Committee (PDCO)

-- Enrollment Expected to Begin Next Month -- SEATTLE , June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its

-- OMS824 Achieves High Target Occupancy without Causing Movement Disorders Seen with Other PDE10 Inhibitors -- SEATTLE , May 31, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its

-- Phase 1 Clinical Trial Expected to Begin Early Next Quarter -- SEATTLE, Wash. , May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the

-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE , May 23, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the

SEATTLE , May 22, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , May 14, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9 , 2013.  The shares were sold at a price of $4.14 per share, which represented a two percent

SEATTLE , May 10, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

SEATTLE , May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013 , for gross proceeds of $16.2 million .

-- Phase 2 Clinical Trial Slated to Begin This Year -- SEATTLE , May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration ( FDA ) for the development of OMS824 for the treatment of

-- Centralized Procedure Used for Products that Represent Therapeutic Innovation -- SEATTLE , April 30, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application (MAA)

-- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis -- SEATTLE , April 25, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the

SEATTLE , April 24, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12 th

SEATTLE , April 19, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of

-- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review -- SEATTLE , April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S.

- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE , April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS),

-- Support Advancing Initial Clinical Indication of Atypical Hemolytic Uremic Syndrome -- SEATTLE , April 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding lectin-associated serine

SEATTLE , March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present

-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 -- SEATTLE , March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding

-- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors -- SEATTLE , March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1

-- Clinical Entry Planned for Second Half of 2013 -- SEATTLE , March 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has elucidated the mechanism of action of its phosphodiesterase 7 (PDE7) inhibitors in the neural network shown to be responsible for addiction in

SEATTLE , March 18, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial

SEATTLE , March 1, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- IND/CTA Submission Expected in the Second Quarter of 2013 -- SEATTLE , Feb. 7, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros ' mannan-binding lectin associated serine protease-2

-- Market Launch Expected First Half of 2014 -- SEATTLE , Jan. 22, 2013 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients

- Expands "Unlocking" Capability Beyond Class A Orphan GPCRs - SEATTLE , Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G

-- Second Meniscectomy Phase 3 Clinical Trial Enrollment Targeted for First Half of 2013 -- -- Company to Host Conference Call Today at 5:00 p.m. EST -- SEATTLE , Dec. 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported results from its first pivotal Phase 3 clinical trial

-- Single-Ascending-Dose Study Results Support Continued Advancement of Phase 1 Trial-- SEATTLE , Dec. 6, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating

SEATTLE , Nov. 29, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the

SEATTLE , Nov. 20, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A.

-Remyelination May Provide a Novel Treatment for Multiple Sclerosis Patients- SEATTLE , Nov. 15, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have

SEATTLE , Nov. 13, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) has noted the fall in its share price over the last week of trading.  Omeros is not aware of any reason that justifies this decrease. As disclosed in Omeros ' recent press releases and its Quarterly Report on Form 10-Q filed

SEATTLE , Nov. 9, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

SEATTLE , Nov. 9, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today is addressing misleading statements in a press release issued yesterday by Davis Wright Tremaine , the law firm representing Richard J. Klein , Omeros ' former chief financial officer with whom Omeros recently settled a

SEATTLE , Nov. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it will present data from its first pivotal Phase 3 clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 10 through November

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE , Nov. 5, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported positive data from the second of its two pivotal Phase 3 clinical trials

-- Data Expected Before Year End -- SEATTLE , Nov. 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros ' phosphodiesterase 10 (PDE10) program. 

-- Equals Number of GPCRs Targeted by over 30 Percent of Marketed Drugs -- SEATTLE , Oct. 24, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs).

-Cathy Melfi, Ph.D. to Head Regulatory Function and Dr. Albert Yu to Serve as VP, Clinical Development- SEATTLE , Oct. 18, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting

-- Results Expected this Quarter -- SEATTLE , Oct. 3, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the last patient has been enrolled in the Company's second Phase 3 clinical trial evaluating OMS302 for use during intraocular lens replacement (ILR) surgery.

-- Data from First Phase 1 Clinical Trial Expected in 2012 -- SEATTLE , Oct. 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the Company's OMS824 Investigational New Drug Application (IND) has been cleared by the U.S. Food and Drug Administration (FDA).  With this

SEATTLE , Sept. 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that its Board of Directors has elected Arnold C. Hanish to serve on the Company's Board. Mr. Hanish has also been appointed to serve as Chairman of the Audit Committee.

-- Omeros' Proprietary Antibody Platform Enables Rapid Discovery -- SEATTLE , Sept. 19, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the National Institute of Mental Health (NIMH) awarded a grant to the Company for its proprietary antibody discovery (DTLacO) platform.

-- Data from First Phase 1 Clinical Trial Expected in 2012 -- SEATTLE , Sept. 6, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration ( FDA ) to initiate clinical trials

SEATTLE , Sept. 4, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- Five Additional Orphans Connected to Autism, Osteoarthritis and Neuropsychiatric Disorders -- SEATTLE , Aug. 15, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of five additional orphan G

SEATTLE , Aug. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

-- On Track to Report Data Later this Year -- SEATTLE , Aug. 8, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the completion of enrollment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy

SEATTLE , Aug. 7, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

-- Mechanism of Activation of Complement System's Alternative Pathway Identified -- SEATTLE , July 31, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it believes it has identified the proteins that activate the alternative pathway of the complement system, an important

-- Omeros Has Notified FDA of Intent to Submit Investigational New Drug Application this Quarter -- SEATTLE , July 18, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that OMS824, the lead compound in the Company's phosphodiesterase 10 (PDE10) program for schizophrenia, has

SEATTLE , July 2, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on June 27, 2012 , relating to the sale of 3,365,854 shares of its common stock

SEATTLE , June 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,926,830 shares of its common stock at a price to the public of $10.25 per share for gross proceeds of $30.0 million .

SEATTLE , June 26, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to

-- 24-Patient Study to Confirm Low Levels of Systemic Exposure Observed in Preclinical Studies -- SEATTLE , May 31, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced the initiation of the planned pharmacokinetic (PK) substudy in its Phase 3 clinical program evaluating OMS302

SEATTLE , May 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , May 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

-- Now Totaling 37, Omeros Has Unlocked Over 45 Percent of the Class A Orphan GPCRs -- SEATTLE , May 3, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors

SEATTLE , May 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

--Data from Trial Expected in Second Half of 2012-- SEATTLE , April 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that patient enrollment has begun in the Company's second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

SEATTLE , March 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming intraocular surgical methods of using OMS302, the Company's ophthalmological PharmacoSurgery™ product.

SEATTLE , March 28, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , March 27, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the

SEATTLE , March 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial

-- Company to Host Conference Call Today at 9:00 a.m. EDT-- SEATTLE , March 13, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.  OMS302 met its primary

SEATTLE , March 1, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory

-- Latest Receptors Linked to Multiple Sclerosis, Schizophrenia, Rheumatoid Arthritis, Cancer Stem Cells, Bone Disorders, New Hair Follicle Generation and Wound Repair -- SEATTLE , Feb. 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that

--Four Additional Orphans Unlocked by Omeros Linked to Ovarian and Prostate Cancer, Obesity and Diabetes, Suspended Animation and Schizophrenia-- SEATTLE , Feb. 23, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with

-- Potential for Non-Addictive Analgesics --   SEATTLE , February 21, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has been awarded a grant of $1.04 million from the National Institute on Drug Abuse (NIDA) to fund further drug development against neuromedin U

SEATTLE , Feb. 8, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A.

SEATTLE , Feb. 7, 2012  /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which Omeros believes expands opportunities for the

SAN DIEGO , Feb. 1, 2012 /PRNewswire/ --  BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new 15-year lease with Omeros Corporation (NASDAQ: OMER) for BioMed's Waterfront Research Center property located in Seattle , Washington.  A clinical-stage biopharmaceutical company

--Five Additional Orphans Unlocked by Omeros Linked to Liver Cancer, Cognitive Impairments, Cardiovascular and Inflammatory Disorders-- SEATTLE , Jan. 10, 2012 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of

Four Additional Orphans Unlocked by Omeros Linked to Melanoma, Anxiety, Gastrointestinal Disorders and Respiratory and Immune Disorders-- SEATTLE, Nov. 30, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that with its identification of compounds that interact

SEATTLE , Nov. 29, 2011 /PRNewswire/ --  Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the European Medicines Agency (EMA) a letter of intent to file its Paediatric Investigation Plan (PIP) for OMS302, the Company's product candidate for use during intra-ocular lens

  SEATTLE , Nov. 22, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory

SEATTLE, Nov. 8, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its

Data from Initial Trial Expected in First Quarter of 2012-- SEATTLE, Oct. 11, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement

Orphans Linked to Cancer, Metabolism, Eye, Immune and CNS Disorders-- SEATTLE, Sept. 13, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors

SEATTLE, Sept. 6, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that

SEATTLE, Aug. 9, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its

SEATTLE, Aug. 3, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, June 29, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported the publication of results from a Phase 2 trial investigating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. OMS103HP is Omeros' product candidate being developed for use

SEATTLE, June 27, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an

SEATTLE, June 2, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

Omeros Has Now Discovered Compounds for Approximately 10% of Class A Orphans-- SEATTLE, May 31, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) GPR27 and GPR173.

Extends Patent Protection for OMS103HP into 2020 -- SEATTLE, May 24, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming the composition of OMS103HP, the Company's arthroscopic

Phase 3 Clinical Programs Advancing for Two PharmacoSurgery(TM) Products -- SEATTLE, May 19, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that it is advancing two of its product candidates from its PharmacoSurgery(TM) platform - OMS103HP for arthroscopic

SEATTLE, May 10, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced its financial

Promising Data for the Treatment of Nicotine Addiction -- SEATTLE, May 5, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that its phosphodiesterase 7 (PDE7) inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

SEATTLE, April 27, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, April 19, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences

SEATTLE, April 11, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

Publication is Honored in the Journal of Biological Psychiatry -- SEATTLE, April 7, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on the PPAR-gamma agonists it is developing in its Addiction franchise has been published in the April 1, 2011 issue of

SEATTLE, April 4, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.

Webcast Conference Call Scheduled for 5:30pm EDT Today-- SEATTLE, March 31, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central

OMS302 Maintains Pupil Dilation During Cataract Surgery and Reduces Postoperative Pain -- SEATTLE, March 23, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation,

SEATTLE, March 15, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for

SEATTLE, March 2, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors (GPCRs) linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12).

Promising Data for the Treatment of Addiction and Compulsive Disorders -- SEATTLE, Feb. 22, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd.

Publication is Honored in the Journal of Biological Chemistry -- SEATTLE, Feb. 10, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that research on the antifibrinolytic agents it is developing has been published in the February 11, 2011 issue of the Journal of

SEATTLE, Feb. 1, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has confirmed that OMS103HP is eligible to be submitted for marketing approval in the European Union (EU) through the EMA centralized procedure.

IND-Enabling Activities Already Initiated -- SEATTLE, Jan. 5, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents.

SEATTLE, Dec. 29, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical

SEATTLE, Nov. 24, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, Nov. 23, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has completed the

SEATTLE, Nov. 17, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced the appointment of Kenneth M.

SEATTLE, Nov. 9, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the

SEATTLE, Nov. 4, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third

SEATTLE, Nov. 3, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has been awarded non-taxable

Company to Host Webcast Conference Call Today at 4 p.m. EDT SEATTLE, Oct 25, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous

SEATTLE, Oct 22, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that the Company will host a webcast

SEATTLE, Oct 15, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, Oct 14, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6

SEATTLE, Sept 08, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, Aug 10, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and

Company to Issue Second Quarter Financial Results After Market on August 10th SEATTLE, Aug 05, 2010 /PRNewswire via COMTEX/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of

SEATTLE, July 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd.

SEATTLE, July 27, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has enrolled

Opportunity for Development of Unprecedented Number of Novel Drug Targets - SEATTLE, June 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors

SEATTLE, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.

SEATTLE, May 13, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company, today announced that, based on successful preclinical studies, the Company has selected a clinical candidate for its MASP-2 antibody program and has initiated

SEATTLE, May 12, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for

SEATTLE, May 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy

SEATTLE, April 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A.

Company Also Announces Two Additions to Management Team- SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the

Webcast Conference Call to be Held Today at 4:30pm ET - SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, demonstrated that patients

SEATTLE, March 15 /PRNewswire-FirstCall/ --Omeros Corporation (Nasdaq:OMER - News), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it will hold a conference call

SEATTLE, March 9, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

SEATTLE, Jan 28, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be

SEATTLE, Dec 09, 2009 /PRNewswire via COMTEX News Network/ -- Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company's Board. Mr. Spiegelman has also been appointed to serve as Chairman of the Audit Committee.

SEATTLE, Nov 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34

SEATTLE, WA, Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it

SEATTLE, Wash., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation today announced the pricing of its initial public offering of 6.82 million shares of its common stock at a price of $10.00 per share. The underwriters have the option to purchase up to an additional

Seattle, WA - August 11, 2009 - Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery™ product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation

Seattle, WA - August 5, 2009 - Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros'

Seattle, WA - January 28, 2009 - Omeros Corporation today announced that it was awarded $3.1 million in a second tranche of equity and grant funding from The Stanley Medical Research Institute (SMRI) to support late-stage preclinical development of the Company's proprietary product candidates for

Seattle, Washington - January 6, 2009 - Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute evaluating Omeros' recent discovery of a new target for the

Seattle, WA - December 9, 2008 - Omeros Corporation today announced favorable results from a Phase 1 vehicle-controlled study of OMS201, another of Omeros' PharmacoSurgery™ product candidates, for use during urological surgery. The Phase 1 study of OMS201 enrolled patients undergoing endoscopic

Seattle, WA and Chicago, IL, September 24, 2008 - Omeros Corporation, a Seattle-based biopharmaceutical company, today announced the establishment of a $20 million debt facility with BlueCrest Capital Finance. The facility consists of a $5 million term loan drawn by Omeros at closing and the right,

Seattle, Washington and Sunnyvale, California - September 17, 2008 - Omeros Corporation and The Parkinson's Institute and Clinical Center today announced that they have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders.

Third PharmacoSurgery™ Platform Product Candidate in Clinical Trials Seattle, Washington - September 9, 2008 - Omeros Corporation today announced that it is enrolling patients in a Phase1/Phase 2 study of OMS302, the Company's third PharmacoSurgery™ product candidate, for use during ophthalmologic

Seattle, WA - August 26, 2008 - Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic

Seattle, USA and Oslo, Norway- August 19, 2008 - Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human

Seattle, Washington - May 20, 2008 - Omeros Corporation today announced that it has begun patient enrollment for the Phase 1 study of OMS201, the Company's second PharmacoSurgeryTM drug product candidate, for use during urological surgery. At least 24 patients undergoing unilateral ureteroscopic

Seattle, WA - February 12, 2007 - Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors, including Aravis Ventures, ARCH Venture Partners, subsidiaries of American Financial Group, Grosvenor Funds, Novartis Venture Fund,

Seattle, WA -- January 9, 2007 - Omeros Corporation announced today that the Stanley Medical Research Institute (SMRI) will provide up to $9 million in equity and grant funding toward the development of Omeros' proprietary drug candidate for the treatment of schizophrenia.

-Acquisition adds world-renowned scientists and expands pipeline- Seattle, WA - September 7, 2006 - Omeros Corporation, a Seattle-based biopharmaceutical company, announced today that it has acquired Nura, Inc., a company developing treatments for pain and other central nervous system disorders